Biogen(US:BIIB) 智通财经网·2025-07-31 12:47Core Viewpoint - Biogen's latest quarterly earnings report exceeded Wall Street expectations, driven by strong sales of Alzheimer's drug Leqembi, prompting the company to raise its financial guidance [1][2] Financial Performance - Biogen reported total sales of $2.6 billion for the second quarter, a 7% year-over-year increase, surpassing analyst expectations of $2.3 billion [1] - The company's net profit for the quarter was $635 million, up from $584 million in the same period last year, with adjusted earnings per share reaching $5.47, a 4% increase and well above the average analyst estimate of $3.86 [1] - Revenue from the Alzheimer's drug Leqembi was $125 million in the latest quarter, significantly exceeding Wall Street's expectations [1] Product Performance - The Alzheimer's treatment Leqembi, developed in collaboration with Eisai, faced initial logistical challenges and regulatory hurdles but has shown strong sales growth, with previous quarters reporting $87 million and $96 million in sales [1] - The rare disease treatment Skyclarys contributed approximately $130 million in revenue, meeting market expectations [2] Future Outlook - Biogen raised its earnings per share forecast for 2025 from the previous range of $14.50-$15.50 to $15.50-$16.00 and adjusted its full-year revenue forecast to be flat compared to 2024 [2] - The company aims to alleviate investor concerns regarding the decline of its traditional multiple sclerosis business by focusing on new drug sales, including Leqembi [2] Strategic Initiatives - Since taking over as CEO in late 2022, Chris Viehbacher has focused on transforming Biogen by enhancing Leqembi sales, implementing cost reductions, and decreasing reliance on high-risk neurological treatments [2] - Biogen is open to acquiring new immunotherapy and rare disease treatment assets as part of its strategy to strengthen its research and development pipeline [2] Production and Tariff Policy - Biogen stated that the potential cancellation of drug tariff exemptions in the U.S. would not significantly impact its annual performance due to the majority of its U.S. revenue coming from domestic production [3] - To mitigate potential tariff risks, the company announced a $2 billion investment to expand its core manufacturing facility in North Carolina [3]